Chemotherapy and Radiotherapy for Anal Canal Carcinoma—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Drs Musio and Codacci-Pisanelli suggest that the delay in initiating chemoradiation in the cisplatin-based treatment arm of our trial may be the reason for the adverse outcome compared with the mitomycin-based treatment arm. The study by Forastiere et al1 did conclude that concurrent chemoradiation was superior to radiotherapy alone or the sequence of induction chemotherapy followed by radiotherapy in patients with head and neck cancer. We do not draw a parallel between that study and ours because of completely different designs and hypotheses. However, in the study by Forastiere et al, the use of induction chemotherapy did provide a slight advantage over radiation alone for local control, but it was statistically nonsignificant. It could be that an investigation of induction chemotherapy followed by chemoradiation compared with chemoradiation in patients with head and neck cancer would provide some advantage. That strategy did not work in the patients with anal . . . [Full Text of this Article]
Jaffer A. Ajani, MD
jajani@mdanderson.org
University of Texas M. D. Anderson Cancer Center
Houston
Kathryn A. Winter, MS
Radiation Therapy Oncology Group
Philadelphia, Pennsylvania
Leonard L. Gunderson, MD
Mayo Clinic
Scottsdale, Arizona
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Chemotherapy and Radiotherapy for Anal Canal Carcinoma
Daniela Musio and Giovanni Codacci-Pisanelli
JAMA. 2008;300(12):1410-1411.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Off-label prescribing: a call for heightened professional and government oversight.
Dresser and Frader
J Law Med Ethics 2009;37:476-486.
|
